Elsevier

The Lancet

Volume 358, Issue 9277, 21 July 2001, Pages 207-208
The Lancet

Fast track — Research Letters
Linezolid resistance in a clinical isolate of Staphylococcus aureus

https://doi.org/10.1016/S0140-6736(01)05410-1Get rights and content

Summary

The new oxazolidinone antimicrobial, linezolid, has been approved for the treatment of infections caused by various gram-positive bacteria, including meticillin-resistant Staphylococcus aureus (MRSA) and vancomycin-resistant enterococci (VRE). Although instances of linezolid resistance in VRE have been reported, resistance has not been encountered among clinical isolates of S aureus. We have characterised an MRSA isolate resistant to linezolid that was recovered from a patient treated with this agent for dialysis-associated peritonitis.

References (5)

There are more references available in the full text version of this article.

Cited by (952)

View all citing articles on Scopus
View full text